Drake Richard R, Cazare Lisa H, Semmes O John, Wadsworth J Trad
Eastern Virginia Medical School, Center for Biomedical Proteomics, Department of Microbiology & Molecular Cell Biology, Norfolk, VA 23507, USA.
Expert Rev Mol Diagn. 2005 Jan;5(1):93-100. doi: 10.1586/14737159.5.1.93.
Initial clinically oriented applications of emerging proteomic technologies that aim to identify biomarkers for head and neck squamous cell carcinoma diagnostics have yielded promising results. The development of new proteomic diagnostics remains critical for the early detection of head and neck squamous cell carcinoma at more treatable stages. Prognostic markers for disease recurrence and treatment sensitivities are also required. In this overview of current biomarker identification strategies for head and neck squamous cell carcinoma, different combinations of mass spectrometry platforms, laser capture microscopy and 2D gel electrophoresis procedures are summarized as applied to readily available clinical specimens (tissue, blood and saliva). Issues related to assay reproducibility, management of large data sets and future improvements in clinical proteomics are also addressed.
旨在识别头颈部鳞状细胞癌诊断生物标志物的新兴蛋白质组学技术最初的临床应用已取得了令人鼓舞的成果。新的蛋白质组学诊断方法的开发对于在更易治疗阶段早期检测头颈部鳞状细胞癌仍然至关重要。还需要疾病复发和治疗敏感性的预后标志物。在这篇关于头颈部鳞状细胞癌当前生物标志物识别策略的综述中，总结了质谱平台、激光捕获显微镜和二维凝胶电泳程序的不同组合应用于现成的临床标本（组织、血液和唾液）的情况。还讨论了与检测重现性、大数据集管理以及临床蛋白质组学未来改进相关的问题。
